Clinical Trial

A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany

Study acronym: ASC2ADHERE
Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this study is to assess the real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) patients who were either newly diagnosed or previously treated with one ATP-competitive tyrosine kinase inhibitor (TKI).
Protocol Amendment History 6 changes
notable Trial sites expanded: 54 -> 57 locations 2026-08-13
notable Trial sites expanded: 41 -> 54 locations 2026-07-28
notable Trial sites expanded: 29 -> 41 locations 2026-07-08
notable Trial sites expanded: 15 -> 29 locations 2026-06-13
critical Recruitment opened 2026-05-16
notable Trial sites expanded: 0 -> 15 locations 2026-05-16
Trial Details
NCT Number NCT07549516
Lead Sponsor Novartis Pharmaceuticals
Conditions Leukemia, Chronic Myeloid
Enrollment 380 participants
Start Date 2026-04-17
Primary Completion 2030-09-30 (estimated)
Study Completion 2030-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-12